Minnesota medical marijuana patients are worried after news broke that one of the state’s two cannabis providers is experiencing a distribution delay, leaving them with scarce supplies for treatment.
According to the Star Tribune, LeafLine Labs has let patients know that there will be delay in when medical marijuana will be available again.
One patient, Katie Kennedy, called on Monday to refill her supply to both manage her fibromyalgia and chronic pain and her son’s Tourette Syndrome and autism. A representative told Kennedy that she would have to wait until Friday to receive a new supply, but gave her a small amount to get her son through the week.
“I will be in great pain by the end of the week,” Kennedy said.
LeafLine’s Chief Executive Dr. Andrew Bachman addressed the issue in a written statement, assuring patients that the current lack in supply will be brief.
Bachman attributed the shortage to the Thanksgiving holiday, as well as a hold up by a third-party lab that is used to test the company’s marijuana products before distribution.
“LeafLine Labs has plenty of inventory, but due to some unforeseen delays at the lab, including the recent holiday, we are still waiting for our certificate of analysis to release more product to our patients,” he said.
Clients were directed to LeafLine’s St. Paul facility, as the Eagan facility is closed for the week.
Kennedy was one of many Minnesota medical marijuana patients who complained via social media, several claiming they were all offered different excuses for the shortage ranging from an influx of patients to the need to upgrade dated equipment.
A spokesman for the Minnesota Department of Health said the state was alerted about the shortage and is examining the issue.
One patient named Patrick McClellan is not so worried about what the lack of supply means for him, but rather what the current circumstances could mean for chronic pain patients who used to manage their ailments with opioids.
“That could be extremely dangerous,” he said.
Kennedy asserted that the LeafLine has been a supportive company up until this incident.
“Running out of our medicine shows that we need more options in the state,” she said.